Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lysine Clear all
Recruiting Phase 3 Interventional

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

NCT06070350
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma Injury
Interventions
Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT)
Biological · Drug
Lead sponsor
Philip Spinella
Other
Eligibility
Up to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

NCT04081220
View directory record Official record
Conditions
Thrombocythemia, Essential
Interventions
IMG-7289
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting Early Phase 1 Interventional

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

NCT05160597
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided Biopsy
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma

NCT06521775
View directory record Official record
Conditions
Metastatic Adenoid Cystic Carcinoma
Interventions
Computed Tomography, Electronic Health Record Review, Ga-68 PSMA-11, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Phase 1 Interventional

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

NCT03826992
View directory record Official record
Conditions
Leukemia
Interventions
Vyxeos, Venetoclax
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 39 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Early Phase 1 Interventional

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

NCT04310540
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Biopsy, Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting Phase 3 Interventional

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

NCT03582774
View directory record Official record
Conditions
Recurrent Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Other · Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Phase 1 Interventional

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05597306
View directory record Official record
Conditions
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions
Bomedemstat, Venetoclax
Drug
Lead sponsor
Terrence J Bradley, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 1Phase 2 Interventional

Study of ZIO-201 in Advanced Sarcoma

NCT00439686
View directory record Official record
Conditions
Advanced Sarcoma
Interventions
ZIO-201
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Santa Monica, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 5, 2026, 10:05 AM EDT
Terminated Phase 2 Interventional

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

NCT01698281
View directory record Official record
Conditions
Breast Cancer
Interventions
AEZS-108, SCCC, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

Aztreonam Lysine for Pseudomonas Infection Eradication Study

NCT01375049
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting Phase 3 Interventional

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed No phase listed Observational

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

NCT03857087
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

NCT03353740
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 5, 2026, 10:05 AM EDT
Not listed Phase 1 Interventional

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

NCT05475210
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
177Lu-DOTA-EB-TATE, Amino Acid Solution
Drug · Other
Lead sponsor
Molecular Targeting Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Phase 2 Interventional

Leucine in Midlife Depression

NCT06580145
View directory record Official record
Conditions
Major Depression
Interventions
L-leucine, L-lysine
Drug
Lead sponsor
Emory University
Other
Eligibility
35 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
INCB059872
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Miami, Florida • Tamarac, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Sep 5, 2026, 10:05 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Lysine-Specific Demethylase 1

NCT01702688
View directory record Official record
Conditions
Hypertension
Interventions
Para-aminohippuric Acid, Angiotensin II
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 5, 2026, 10:05 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Use of Tranexamic Acid in Facial Fillers

NCT04373603
View directory record Official record
Conditions
Injection Site Bruising
Interventions
Tranexamic acid, Saline, Hyaluronic acid
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 3 Interventional

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

NCT02940262
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
1,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 5, 2026, 10:05 AM EDT